GLOW — Fixed-Duration Ibrutinib Plus Venetoclax in Older or Comorbid Patients With Untreated Chronic Lymphocytic Leukemia (GLOW)

Phase 3 · 2021 · Chronic Lymphocytic Leukemia

Design

Randomized trial of fixed-duration oral ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab.

Population

Previously untreated chronic lymphocytic leukemia in older patients (≥65) or younger patients with comorbidities.

Primary Endpoint

progression-free survival (PFS)

Key Result

Progression-free survival strongly favored the all-oral fixed-duration regimen (HR 0.216), with superior undetectable MRD rates.

Guideline Impact

Supports fixed-duration ibrutinib plus venetoclax as a chemotherapy-free option for treatment-naive CLL